Microsphere comprising thyrazepatide, method for preparing same, and pharmaceutical composition comprising same

Microspheres encapsulating tyrzepatide with PLGA for controlled release address the limitations of single-mechanism T2D treatments and tirzepatide administration, offering sustained glycemic control and reduced side effects by maintaining effective drug concentrations and improving patient compliance.

WO2024242410A1PCT designated stage expired Publication Date: 2024-11-28AULBIO CO LTD
View PDF 20 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/006716
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-19
Filing Date
2024-05-17
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current treatments for type 2 diabetes (T2D) using incretin mimetics or dipeptidyl peptidase IV (DPP-IV) inhibitors rely on a single mechanism of action, leading to inadequate glycemic control and side effects like nausea, while tirzepatide administration is limited by enzymatic degradation and absorption issues, necessitating a formulation for sustained release to manage pain and inflammatory reactions at injection sites.

Method used

Development of microspheres containing tyrzepatide, a GLP-1/GIP receptor agonist, using a biocompatible polymer like polylactide-co-glycolide (PLGA) that encapsulates the drug at high concentrations, allowing for controlled and extended release, reducing initial burst and maintaining effective drug concentration in the blood for an extended period.

Benefits of technology

The microspheres provide stable drug release over time, extending the administration cycle, increasing patient compliance, and reducing side effects, while enabling a higher loading dose for improved glycemic control and weight management.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024006716_28112024_PF_FP_ABST
    Figure KR2024006716_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to: microspheres comprising thyrazepatide or a pharmaceutically acceptable salt thereof, and a biocompatible polymer; a method for preparing same; and a pharmaceutical composition comprising same. The microspheres comprising thyrazepatide according to the present invention can maintain an effective concentration of a drug in blood for a long period of time by exhibiting stable drug release for a long period of time, thereby extending a drug administration cycle, increasing drug compliance of a patient, and reducing side effects caused by rapid initial drug release.
Need to check novelty before this filing date? Find Prior Art

Description

Microspheres containing tirzepatide, method for preparing the same, and pharmaceutical composition containing the same

[0001] This application claims the benefit of priority to Korean Patent Application No. 10-2023-0065250, filed May 19, 2023, the entire contents of which are incorporated herein by reference.

[0002] The present invention relates to microspheres comprising tirzepatide, a method for producing the same, and a pharmaceutical composition comprising the same.

[0003] T2D is the most common form of diabetes, accounting for approximately 90% of all diabetes cases. T2D is characterized by high blood sugar levels due to insulin resistance. Current standard treatment for T2D includes diet and exercise, along with available oral and injectable glucose-lowering medications. Despite this, many T2D patients remain inadequately controlled. Currently available incretin mimetics or dipeptidyl peptidase IV (DPP-IV) inhibitors utilize only a single mechanism of action established for glycemic control. There is a need for compounds for T2D that utilize dual mechanisms of action.

[0004] GIP is a 42-amino acid gastrointestinal regulatory peptide that plays a physiologically important role in glucose homeostasis by stimulating insulin secretion from pancreatic beta cells in the presence of glucose and protecting pancreatic beta cells. GLP-1 is a 37-amino acid peptide that stimulates insulin secretion, protects pancreatic beta cells, and inhibits glucagon secretion, gastric emptying, and food intake, all of which induce weight loss. GIP and GLP-1 are known as incretins; incretin receptor signaling has physiologically important functions in glucose homeostasis. In normal physiology, GIP and GLP-1 are secreted from the digestive tract after a meal, and these incretins enhance physiological responses to food, including satiety, insulin secretion, and nutrient processing. Patients with T2D have an impaired incretin response.

[0005] GLP-1 analogue dosing has been shown to be limited by adverse effects, such as nausea and vomiting, and as a result, does not achieve full efficacy in glycemic control and weight loss. GIP alone has limited glucose-lowering capacity in humans with type 2 diabetes. Both natural GIP and GLP-1 are rapidly inactivated by the ubiquitous protease DPP IV, and therefore can only be used for short-term metabolic control.

[0006] Specific GIP analogues exhibiting both GIP and GLP-1 activity are disclosed in WO 2013 / 164483, WO 2014 / 192284, and WO 2011 / 119657. Furthermore, these GIP analogues, Mounjaro ® and Zepbound ® (tirzepatide), are commercially available.

[0007] Tirzepatide is often administered in the form of an injection due to several barriers, including enzymatic degradation in the gastrointestinal tract and intestinal mucosa, insufficient absorption from the intestinal mucosa, and first-pass metabolism in the liver.

[0008] Injectables containing tirzepatide are formulated to be administered directly by patients (self-administered) for the continuous management of obesity or diabetes, so it is very important to manage pain and inflammatory reactions that may occur at the injection site.

[0009] Therefore, there is a need for a formulation that can maintain long-term efficacy with a single injection to facilitate the management of pain, inflammation, and other symptoms, as described above, and to improve administration convenience. The currently available liquid formulation of tirzepatide (administered once a week) is easy to manufacture and administer, but increasing the dosage can lead to fatal side effects. Therefore, its use for the purpose of maintaining long-term efficacy is limited.

[0010] Recently, various formulation technologies have been employed to address these shortcomings and provide sustained and controlled release of pharmacologically active substances. Among these, long-acting microspheres, or injectables, are microspheres in which the pharmacologically active substance is encapsulated within a biocompatible polymer. These microspheres are designed to ensure uniform drug release from the microspheres upon subcutaneous or intramuscular injection.

[0011] In order for such long-acting microparticle-based release formulations to actually lead to the effects of improved administration convenience and reduced administration dose, it is necessary to develop a technology that allows high-dose drug to be contained within the microparticles.

[0012] [Prior Art Literature]

[0013] [Patent Document]

[0014] PCT Publication WO 2013 / 164483

[0015]

[0016] The inventors of the present invention have conducted repeated research to solve the above-mentioned problems of the prior art and have developed microspheres in which tirzepatide is encapsulated at a high concentration, and which continuously release tirzepatide for a long period of time without an initial burst.

[0017] Therefore, the present invention aims to provide tirzepatide microspheres, a method for preparing the same, and a pharmaceutical composition comprising the same, which exhibit long-term stable drug release and maintain an effective blood concentration of the drug for a long period of time, thereby extending the drug administration cycle, increasing patient compliance, and reducing side effects caused by rapid initial drug release.

[0018]

[0019] In order to solve the above problem, the present invention,

[0020] Microspheres comprising tirzepatide or a pharmaceutically acceptable salt thereof and a biocompatible polymer,

[0021] The above tirzepatide or a pharmaceutically acceptable salt thereof is contained in an amount of 9 wt% or more based on the total weight of the microparticles,

[0022] The biocompatible polymer is polylactide-co-glycolide (PLGA) having an intrinsic viscosity of 0.15 dL / g to 1.7 dL / g and provides microspheres having a molar ratio of lactide to glycolide of 50:45 to 55.

[0023]

[0024] In addition, the present invention

[0025] (a) a step of preparing a dispersion phase by dispersing tirzepatide or a pharmaceutically acceptable salt thereof and a biocompatible polymer in one or more solvents;

[0026] (b) a step of adding the manufactured dispersion phase to a continuous phase and stirring to form microspheres; and

[0027] (c) a step of removing the solvent; provides a method for producing microparticles.

[0028]

[0029] In addition, the present invention

[0030] (1) A step of preparing an inner aqueous phase (W1) by dissolving or dispersing tirzepatide or a pharmaceutically acceptable salt thereof in a solvent;

[0031] (2) A step of preparing an oil phase (O) by dissolving a biocompatible polymer in one or more solvents;

[0032] (3) A step of dispersing an internal phase (W1) in the oil phase (O) to prepare a water-in-oil (W1 / O) type emulsion;

[0033] (4) A step of forming microspheres by dispersing the water-in-oil (W1 / O) type emulsion into an external continuous phase (W2) to produce a water-in-oil (W1 / O / W2) type emulsion; and

[0034] (5) A method for manufacturing microparticles is provided, including a step of removing the solvent.

[0035]

[0036] In addition, the present invention

[0037] The present invention provides a pharmaceutical composition for preventing or treating diabetes, obesity, hypertension, hyperlipidemia, non-alcoholic steatohepatitis, metabolic steatohepatitis, cardiovascular disease, or degenerative neurological disease, comprising the microparticles of the present invention and a pharmaceutically acceptable carrier.

[0038]

[0039] The tirzepatide microspheres of the present invention exhibit stable drug release over a long period of time, thereby maintaining effective blood drug concentrations for a long period of time. This extends the drug administration cycle, enhances patient compliance, and alleviates side effects caused by rapid initial drug release.

[0040] Furthermore, the method for producing tirzepatide microspheres of the present invention enables the efficient production of microspheres with excellent loading capacity and encapsulation rate. Furthermore, the pharmaceutical composition of the present invention, by including the tirzepatide microspheres, provides excellent effects in the treatment of diabetes, obesity, and other conditions.

[0041]

[0042] Figure 1 is a graph showing the cumulative drug release rate over time after in vivo administration of microspheres manufactured in Example 5 of the present invention.

[0043]

[0044] Hereinafter, the present invention will be described in more detail.

[0045] Unless otherwise defined, all technical terms used in this invention have the same meanings as those commonly understood by those skilled in the art in the relevant field of the present invention. Furthermore, methods or samples similar to or equivalent to those described herein are also included within the scope of the present invention. The contents of all publications cited herein as references are incorporated herein by reference in their entirety.

[0046] In the present invention, tirzepatide or a pharmaceutically acceptable salt thereof may be collectively referred to as tirzepatide.

[0047]

[0048] The present invention relates to microspheres comprising tirzepatide or a pharmaceutically acceptable salt thereof and a biocompatible polymer.

[0049] Currently, tirzepatide is marketed as a liquid injection (administered once a week). While liquid injections are easy to manufacture and administer, increasing the dosage can cause fatal side effects. Therefore, their use for maintaining long-term efficacy is limited.

[0050] The present invention provides tirzepatide microspheres to address the aforementioned problems of the prior art. The tirzepatide microspheres of the present invention exhibit stable drug release over a long period of time, thereby maintaining effective drug concentrations in the blood over a long period of time. Therefore, they can extend the drug administration cycle, improve patient compliance, and alleviate side effects caused by rapid initial drug release.

[0051] In addition, the present invention can show an excellent dose reduction effect by containing a high dose of tirzepatide in microparticles, thereby improving the convenience of administration for patients.

[0052] The above tirzepatide is a GLP-1 / GIP receptor agonist, Ltyrosyl-2-methylalanyl-L-α-glutamylglycyl-L-threonyl-Lphenylalanyl-L-threonyl-L-seryl-L-α-aspartylL-tyrosyl-Lseryl-L-isoleucyl-2-methylalanyl-L-leucyl-L-α-aspartyl-Llysyl-L-isoleucyl-L-alanyl-Lglutaminyl-N 6-[(22S)-22,42-dicarboxy-10,19,24-trioxo-3,6,12,15-tetraoxa-9,18,23-triazadotetracontan-1-oyl]-L-lysyl-L-alanyl-L-phenylalanyl-Lvalyl-L-gluta minyl-L-tryptophyl-L-leucylL-isoleucyl-Lalanylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-Lprolyl-L-prolyl-L-prolyl-Lserinamide (CAS# It is known as 2023788-19-2).

[0053] The above tirzepatide can be used for the prevention or treatment of diabetes (specific example: type 2 diabetes), obesity, preservation of beta-cell function, hypertension, hyperlipidemia, non-alcoholic steatohepatitis, metabolic steatohepatitis, cardiovascular disease, or degenerative neurological diseases such as Alzheimer's disease and Parkinson's disease.

[0054] As the pharmaceutically acceptable salt of the above tirzepatide, any salt commonly used in this field can be used without limitation. The term “pharmaceutically acceptable salt” of the present invention means any and all organic or inorganic addition salts of tirzepatide at a concentration that is relatively non-toxic and harmless to the patient and has an effective effect, and the side effects caused by the salt do not reduce the beneficial effects of the active ingredient. Specific examples of the above pharmaceutically acceptable salts include, but are not limited to, sodium salts, ammonium salts, magnesium salts, calcium salts, potassium salts, acetic acid, benzoic acid, hydroxynaphthoic acid, napadicylate salts, pamoate salts, fumaric acid, oxalic acid, citric acid, tartaric acid, hydrochloric acid, acetic acid, phosphoric acid, maleic acid, mesylic acid, edisylic acid, succinic acid, aspartic acid, pamoic acid, sulfuric acid, benzoic acid, besylic acid, and tosylic acid salts. The above tirzepatide salt can be prepared by conventional techniques, for example, by adding an acid to free tirzepatide to convert it into an acid addition salt, or by converting one acid addition salt into another salt.

[0055] In the present invention, microspheres refer to microspheres manufactured using a biocompatible polymer in which tirzepatide or a pharmaceutically acceptable salt thereof is encapsulated, and are simply referred to as tirzepatide-containing microspheres, tirzepatide microspheres, or microspheres. If tirzepatide or a pharmaceutically acceptable salt thereof is encapsulated in microspheres manufactured using a biocompatible polymer, it may be included in the scope of the present invention depending on the molar ratio and intrinsic viscosity of the biocompatible polymer used.

[0056]

[0057] The tirzepatide or a pharmaceutically acceptable salt thereof may be included in an amount of 9 wt% or more, 15 wt% or more, 20 wt% or more, 25 wt% or more, 30 wt% or more, 35 wt% or more, or 45 wt% or more based on the total weight of the microspheres. If the drug contained in the microspheres is less than 9 wt%, it may be difficult to release the drug for 30 days or more. In addition, the tirzepatide or a pharmaceutically acceptable salt thereof may be included in an amount of 60 wt% or less, 50 wt% or less, 40 wt% or less, 35 wt% or less, 30 wt% or less, 25 wt% or less, or 20 wt% or less based on the total weight of the microspheres.

[0058] The above tirzepatide or a pharmaceutically acceptable salt thereof may be included in a range by a combination of the above lower limit and upper limit.

[0059] In the present invention, the "biocompatible polymer" refers to a polymer that is safe and does not cause cytotoxicity or inflammatory reactions in the body, and is also referred to simply as a polymer in this specification.

[0060] In the present invention, a biocompatible polymer having an intrinsic viscosity of 0.15 dL / g to 1.7 dL / g may be used, preferably a polymer having an intrinsic viscosity of 0.15 dL / g to 1.5 dL / g may be used, and more preferably a polymer having an intrinsic viscosity of 0.15 dL / g to 1.3 dL / g may be used.

[0061] If the intrinsic viscosity of the above biocompatible polymer is less than 0.15 dL / g, the polymer may decompose too quickly, making it difficult to continuously release tirzepatide for a desired period of time. If it exceeds 1.7 dL / g, the polymer may decompose too slowly, resulting in a small amount of tirzepatide released, and thus the drug effect may not be observed.

[0062] In the present invention, the biocompatible polymer may be included in an amount of 91 wt% or less based on the total weight of the microspheres. If the biocompatible polymer is included in an amount exceeding 91 wt%, the proportion of the biocompatible polymer may be relatively high, resulting in a small release of tirzepatide, which may result in no or very slow release of the drug. The biocompatible polymer may be included in an amount excluding the content range of tirzepatide or a pharmaceutically acceptable salt thereof from the total weight of the microspheres. If the microspheres of the present invention further include other components (e.g., PVA, etc.) that can be added to the microspheres, the other components may be further included in an amount of 0.01 to 3 wt%, and in this case, the content of the biocompatible polymer may be reduced by the amount of the other components.

[0063] As the biocompatible polymer, polylactide-co-glycolide (PLGA) can be preferably used, and as the polylactide-co-glycolide (PLGA), at least one selected from copolymers having a molar ratio of lactide to glycolide of 50:45 to 55 or 50:48 to 52 can be more preferably used.

[0064] In one embodiment of the present invention, the microspheres can provide the encapsulated tirzepatide or a pharmaceutically acceptable salt thereof in a controlled or extended release form. The controlled or extended release form may be understood to have the same meaning as "sustained release," "controlled release," or "delayed release."

[0065] In one embodiment of the present invention, the microspheres may have a characteristic in which the release of the encapsulated tirzepatide or a pharmaceutically acceptable salt thereof continues for two weeks or more in an in vitro environment.

[0066] In one embodiment of the present invention, the initial burst release (initial burst within 24 hours) of tirzepatide or a pharmaceutically acceptable salt thereof contained in the microspheres may be 30 wt% or less, 28 wt% or less, 25 wt% or less, 20 wt% or less, 16 wt% or less, 13 wt% or less, 10 wt% or less, 7 wt% or less, 5 wt% or less, 3 wt% or less, or 2 wt% or less.

[0067] In addition, the microspheres of the present invention may continuously release tirzepatide or a pharmaceutically acceptable salt thereof for 14 days or more, preferably 25 days or more. Furthermore, the tirzepatide or a pharmaceutically acceptable salt thereof may continuously release for 30 days or more, 40 days or more, or 50 days or more.

[0068]

[0069] In one embodiment of the present invention, microspheres comprising tirzepatide or a pharmaceutically acceptable salt thereof may be prepared by a solvent evaporation or extraction method using an emulsion, more preferably, an oil-in-water (O / W) type solvent evaporation method in which an O / W type emulsion comprising a biocompatible polymer, tirzepatide or a pharmaceutically acceptable salt thereof, and a dispersion solvent is prepared and the O / W type emulsion is aggregated into microspheres.

[0070] In order to manufacture microspheres by preparing the above O / W type emulsion and coagulating it into polymer microparticles, first, an O / W type emulsion containing a biocompatible polymer, tirzepatide or a pharmaceutically acceptable salt thereof, and a dispersion solvent is prepared.

[0071] The above O / W type emulsion can be manufactured using a conventional method known in the art, and more specifically, it can be manufactured by adding a dispersion phase containing tirzepatide or a pharmaceutically acceptable salt thereof and a biocompatible polymer to a dispersion solvent.

[0072] These microspheres containing tirzepatide or a pharmaceutically acceptable salt thereof can be prepared by coagulating an emulsion into microspheres by solvent extraction and / or solvent evaporation, or by coagulation by ammonolysis with the addition of ammonia or hydrolysis with the addition of an acid or base. A water-insoluble organic solvent that is converted into a water-soluble solvent by the ammonolysis or hydrolysis reaction can be additionally included during the preparation of the emulsion.

[0073] In the case of the above solvent evaporation method, the method is not limited thereto, but for example, the method described in U.S. Patent Nos. 5,271,945, 5,985,309 and 6,471,996, etc., i.e., dissolving a polymer compound in an organic solvent, dispersing or dissolving the drug in the organic solvent, emulsifying in a dispersion medium such as water to prepare an O / W type emulsion, and then diffusing the organic solvent in the emulsion into the dispersion medium and evaporating through the air / water interface, thereby forming polymer microspheres containing tirzepatide or a pharmaceutically acceptable salt thereof.

[0074] The above solvent extraction method includes a conventional solvent extraction method used in the production of microspheres containing tirzepatide or a pharmaceutically acceptable salt thereof, such as effectively extracting the organic solvent in the emulsion droplets using a large amount of solubilizing solvent.

[0075] As a method of simultaneously applying the solvent evaporation method and the solvent extraction method, for example, the methods described in U.S. Patent Nos. 4,389,840, 4,530,840, 6,368,632, 6,544,559, and 6,572,894 can be applied.

[0076] The coagulation by the above ammonolysis process refers to a method of coagulating fine particles by adding ammonia to an O / W type emulsion containing a water-insoluble organic solvent to induce ammonolysis, converting the water-insoluble organic solvent into a water-soluble solvent, for example, as described in Korean Patent No. 918092.

[0077] The coagulation by the above hydrolysis process is a method of coagulating fine particles by adding a base such as NaOH, LiOH, or KOH, or an acid solution such as HCl or H2SO4 to an O / W type emulsion containing a water-insoluble organic solvent, thereby inducing hydrolysis, which is a type of hydrolysis reaction of an ester, and converting the water-insoluble organic solvent into a water-soluble solvent, as described in, for example, Korean Patent Application Nos. 2009-109809 and 2010-70407.

[0078] In one embodiment of the present invention, the microspheres may be W1 / O / W2 (water-in-oil-in-water) microspheres prepared by preparing a W1 / O (water-in-oil) type emulsion comprising an inner phase (W1) in which tirzepatide or a pharmaceutically acceptable salt thereof is dispersed or dissolved in an aqueous solvent; and an oil phase (O) in which a biocompatible polymer is dissolved in a non-aqueous solvent, and dispersing the same in an outer phase (W2). In this case, the microspheres may be prepared by a double emulsification evaporation method.

[0079] In the present invention, microspheres comprising tirzepatide or a pharmaceutically acceptable salt thereof can be manufactured by various microsphere manufacturing methods known in the art (e.g., O / W type, O / O type or W / O / W type solvent evaporation method or solvent extraction method, microsphere manufacturing method by spray drying, microsphere manufacturing method by phase separation, etc.).

[0080] In order to manufacture microspheres by preparing the above W / O / W type emulsion and coagulating it into polymer microparticles, first, a W / O / W type emulsion containing a biocompatible polymer, tirzepatide or a pharmaceutically acceptable salt thereof, and a dispersion solvent is prepared.

[0081] At this time, the W / O / W type emulsion can be manufactured using a conventional method known in the art, and more specifically, it can be manufactured by adding a dispersion phase containing tirzepatide or a pharmaceutically acceptable salt thereof and a biocompatible polymer to a dispersion solvent.

[0082] These microspheres containing tirzepatide or a pharmaceutically acceptable salt thereof can be prepared by coagulating an emulsion into microspheres by solvent extraction and / or solvent evaporation, or by coagulation by ammonolysis with the addition of ammonia or hydrolysis with the addition of an acid or base. A water-insoluble organic solvent that is converted into a water-soluble solvent by the ammonolysis or hydrolysis reaction can be additionally included during the preparation of the emulsion.

[0083] In the case of the above solvent evaporation method, the method is not limited thereto, but for example, the method described in U.S. Patent Nos. 5,271,945, 5,985,309 and 6,471,996, etc., i.e., a polymer compound is dissolved in an organic solvent, a drug is dispersed or dissolved in the organic solvent, and then a W / O / W type emulsion is prepared by emulsifying the organic solvent in the emulsion into the dispersion medium and evaporating it through the air / water interface, thereby forming polymer microspheres containing tirzepatide or a pharmaceutically acceptable salt thereof.

[0084] The above solvent extraction method includes a conventional solvent extraction method used in the production of microspheres containing tirzepatide or a pharmaceutically acceptable salt thereof, such as effectively extracting the organic solvent in the emulsion droplets using a large amount of solubilizing solvent.

[0085] As a method of simultaneously applying the solvent evaporation method and the solvent extraction method, for example, the methods described in U.S. Patent Nos. 4,389,840, 4,530,840, 6,368,632, 6,544,559, and 6,572,894 can be applied.

[0086] The coagulation by the above ammonolysis process refers to a method of coagulating fine particles by adding ammonia to an O / W type emulsion containing a water-insoluble organic solvent to induce ammonolysis, converting the water-insoluble organic solvent into a water-soluble solvent, for example, as described in Korean Patent No. 918092.

[0087] The coagulation by the above hydrolysis process is a method of coagulating fine particles by adding a base such as NaOH, LiOH, or KOH, or an acid solution such as HCl or H2SO4 to a W / O / W type emulsion containing a water-insoluble organic solvent, thereby inducing hydrolysis, which is a type of hydrolysis reaction of ester, and converting the water-insoluble organic solvent into a water-soluble solvent, as described in, for example, Korean Patent Application Nos. 2009-109809 and 2010-70407.

[0088]

[0089] The present invention also

[0090] (a) a step of preparing a dispersion phase by dispersing tirzepatide or a pharmaceutically acceptable salt thereof and a biocompatible polymer in one or more solvents;

[0091] (b) a step of adding the manufactured dispersion phase to a continuous phase and stirring to form microspheres; and

[0092] (c) a step of removing the solvent; provides a method for producing microparticles.

[0093] All of the above-described microspheres can be applied to the method for manufacturing the microspheres of the present invention. Therefore, any redundant descriptions will be omitted below.

[0094] In the above step (a), the weight ratio of the biocompatible polymer to tirzepatide or a pharmaceutically acceptable salt thereof may be 9 times or less.

[0095] In one embodiment of the present invention, the solvent for dissolving the biocompatible polymer or preparing the solvent in a dispersed phase is not particularly limited in type, and for example, dimethyl sulfoxide, dichloromethane, or a mixed solvent thereof may be used. Dichloromethane is particularly preferably used.

[0096] In one embodiment of the present invention, tirzepatide or a pharmaceutically acceptable salt thereof and a biocompatible polymer may be sequentially dissolved and mixed in the same container. At this time, dimethyl sulfoxide or dichloromethane may be used as a solvent, for example.

[0097] The above step (b) is a step of solidifying microspheres by dispersing the dispersed phase prepared in the above step (a) in an external continuous phase to prepare an emulsion solution (O / W).

[0098] In the above step (b), a hydrophilic polymer may be included as a surfactant, and the type thereof is not particularly limited, and any one that can help the dispersed phase including tirzepatide or a pharmaceutically acceptable salt thereof and a biocompatible polymer to form a stable droplet dispersed phase within the external continuous phase may be used.

[0099] The hydrophilic polymer may preferably be selected from the group consisting of methylcellulose, polyvinylpyrrolidone, carboxymethylcellulose, lecithin, gelatin, polyvinyl alcohol, polyoxyethylene-polyoxypropylene block copolymer, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil derivative, and mixtures thereof, and polyvinyl alcohol may be preferably used.

[0100] In the above step (b), the external continuous phase may be a hydrophilic polymer aqueous solution of 0.1 to 6% (w / v), preferably 0.1 to 4% (w / v), wherein the weight average molecular weight of the hydrophilic polymer may be 7,000 to 40,000, and the degree of hydrolysis may be 80 to 90%.

[0101] In the step (b) above, the dispersed phase containing tirzepatide or a pharmaceutically acceptable salt thereof and a biocompatible polymer prepared in the step (a) above is added to the external continuous phase containing the hydrophilic polymer by drop-by-drop or by using an in-line mixer, and stirred vigorously to prepare an emulsion solution (O / W).

[0102] Afterwards, in step (c), the solvent is removed, and the desired microspheres can be obtained after conventional filtration and washing. That is, a step of washing the obtained microspheres using an organic solvent such as ethanol may be included to enhance the initial release inhibition effect, if necessary.

[0103]

[0104] The present invention also

[0105] (1) A step of preparing an inner aqueous phase (W1) by dissolving or dispersing tirzepatide or a pharmaceutically acceptable salt thereof in a solvent;

[0106] (2) A step of preparing an oil phase (O) by dissolving a biocompatible polymer in one or more solvents;

[0107] (3) A step of dispersing an internal phase (W1) in the oil phase (O) to prepare a water-in-oil (W1 / O) type emulsion;

[0108] (4) A step of forming microspheres by dispersing the water-in-oil (W1 / O) type emulsion into an external continuous phase (W2) to produce a water-in-oil (W1 / O / W2) type emulsion; and

[0109] (5) A method for manufacturing microparticles is provided, including a step of removing the solvent.

[0110] The method for manufacturing microspheres of the present invention may be applied to all of the microspheres and methods for manufacturing microspheres described above that are compatible with the manufacturing method (type of biocompatible polymer, intrinsic viscosity thereof, etc.). Therefore, any overlapping information will be omitted below.

[0111] The above step (1) may be, for example, a step of preparing a water phase (W1) by dissolving tirzepatide or a pharmaceutically acceptable salt thereof in distilled water.

[0112] In the above step (2), the type of solvent is not particularly limited, and for example, dimethyl sulfoxide, dichloromethane, or a mixed solvent thereof may be used. In particular, dichloromethane may be preferably used.

[0113] In the above step (3), the weight ratio of the biocompatible polymer to tirzepatide or a pharmaceutically acceptable salt thereof may be 9 times or less.

[0114] The above step (3) is a step of preparing a water-in-oil (W1 / O) type emulsion by dispersing the inner phase (W1) prepared in step (1) into the oil phase (O) prepared in step (2).

[0115] In the above step (3), the weight ratio of the oil phase (O) to the internal phase (W1) may be 1:10 or less.

[0116] The above step (4) is a step of solidifying microspheres by dispersing the water-in-oil (W1 / O) type dispersed phase prepared in the above step (3) in the external continuous phase (W2) to prepare a water-in-oil-in-water (W1 / O / W2) type emulsion solution.

[0117] In the above step (4), the external continuous phase (W2) may include a hydrophilic polymer as a surfactant, and the type thereof is not particularly limited, and any one that can help form a stable droplet-type dispersed phase including tirzepatide or a pharmaceutically acceptable salt thereof and a biocompatible polymer within the external continuous phase may be used.

[0118] The hydrophilic polymer may preferably be selected from the group consisting of methylcellulose, polyvinylpyrrolidone, carboxymethylcellulose, lecithin, gelatin, polyvinyl alcohol, polyoxyethylene-polyoxypropylene block copolymer, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil derivative, and mixtures thereof, and polyvinyl alcohol may be preferably used.

[0119] In the above step (4), the external continuous phase may be a hydrophilic polymer aqueous solution of 0.1 to 6% (w / v), preferably 0.1 to 4% (w / v), and at this time, the weight average molecular weight of the hydrophilic polymer may be 7,000 to 40,000, and the degree of hydrolysis may be 80 to 90%.

[0120] In the above step (4), the dispersed phase (W1 / O) containing the tirzepatide or a pharmaceutically acceptable salt thereof prepared in the above step (3) and the biocompatible polymer is added to the external continuous phase containing the hydrophilic polymer by drop-by-drop or by using an in-line mixer, and stirred vigorously to prepare a water-in-oil-in-water (W1 / O / W2) type emulsion solution.

[0121] Afterwards, in step (5), the solvent is removed, and the desired microspheres can be obtained after conventional filtration and washing. That is, a step of washing the obtained microspheres using an organic solvent such as ethanol may be included to enhance the initial release inhibition effect, if necessary.

[0122]

[0123] In addition, the present invention

[0124] A pharmaceutical composition for preventing or treating diabetes, obesity, hypertension, hyperlipidemia, non-alcoholic steatohepatitis, metabolic steatohepatitis, cardiovascular disease or degenerative neurological disease, comprising the above microparticles and a pharmaceutically acceptable carrier, is provided.

[0125] The pharmaceutical composition according to the present invention can be formulated for parenteral administration.

[0126] The above-described parenteral pharmaceutical composition may further comprise a pharmaceutically acceptable carrier for parenteral administration, which may contain the microspheres alone or may be conventionally added to the pharmaceutical composition. Furthermore, it may further comprise an excipient or diluent. Such carriers include all types of solvents, dispersion media, oil-in-water or water-in-oil emulsions, aqueous compositions, liposomes, microbeads, and microsomes.

[0127] The above-mentioned carrier for parenteral administration may include water, suitable oils, saline solution, aqueous glucose and glycol, etc., and may additionally include stabilizers and preservatives.

[0128] Suitable stabilizers include antioxidants such as sodium bisulfite, sodium sulfite, or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

[0129] The pharmaceutical composition of the present invention may further include, in addition to the above components, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, etc. Other pharmaceutically acceptable carriers and preparations may be referred to as described in the following literature (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).

[0130] The parenteral administration method of the present invention may be administered to a patient (e.g., a person in need of such a drug) or other animals by intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, intravaginal, intrapulmonary, suppository, topical, sublingual or rectal administration, but is not limited thereto.

[0131]

[0132] In the present invention, 'treatment' means any act of improving or beneficially altering an (acute or chronic) disease, disorder, and symptoms resulting therefrom by administering a pharmaceutical composition. In addition, the above 'treatment' broadly includes the meaning of 'prevention,' whereby 'prevention' means any act of suppressing or delaying the onset of a disease and symptoms resulting therefrom by administering a pharmaceutical preparation. The above 'treatment' includes, for example, the obstruction, alleviation, improvement, cessation, suppression, delay, and reversal of the progression of an (acute or chronic) disease, disorder, and symptoms resulting therefrom.

[0133] The preferred total dosage of the pharmaceutical composition or agent of the present invention may be about 0.001 mg to 2,000 mg based on tirzepatide. However, the dosage, frequency, and duration of administration of the pharmaceutical composition will vary depending on factors such as the nature and severity of the condition to be treated, the age and general health of the subject (host), and the subject's (host's) tolerance to the active ingredient. Taking these factors into account, those skilled in the art will be able to determine an appropriate effective dosage of the composition of the present invention. The pharmaceutical composition according to the present invention is not particularly limited in its formulation, administration route, or administration method, as long as it exhibits the effects of the present invention.

[0134] Hereinafter, the present invention will be described in detail using examples. However, the examples according to the present invention may be modified in various ways, and the scope of the present invention should not be construed as being limited to the examples described below. These examples are provided to more fully explain the present invention to those of ordinary skill in the art.

[0135]

[0136] Example 1: Preparation of tirzepatide microspheres

[0137] <Continuous phase manufacturing>

[0138] 1,000 mL of distilled water and 10 g of PVA were weighed and added to the reactor. A 1% (w / v) PVA aqueous solution was prepared by stirring at 1,000 rpm using a homogenizer (Overhead (IKA)).

[0139] <Dispersed phase manufacturing>

[0140] 0.09 g of tirzepatide and 2 ml of dimethyl sulfoxide were weighed and added to an 8 mL vial, and stirred at 150 rpm to dissolve.

[0141] After the above solution was dissolved, 0.8 g of PLGA (inherent viscosity of 0.15 dL / g to 1.7 dL / g) and 2 ml of dichloromethane were added and stirred at 150 rpm to dissolve.

[0142] <Recovery of microspheres>

[0143] After the above process was completed, the dispersed phase was immediately taken with a syringe and placed in a 1 L reactor containing the continuous phase in advance, while stirring with a homogenizer for 7 seconds. The microspheres were then solidified for 24 hours. After solidification was complete, the microspheres were obtained by filtering through a 5 μm filter. The obtained microspheres were then freeze-dried in a freeze-dryer for more than 20 hours.

[0144]

[0145] Example 2: Preparation of tirzepatide microspheres

[0146] <Continuous phase manufacturing>

[0147] 1,000 mL of distilled water and 10 g of PVA were weighed and added to the reactor. A 1% (w / v) PVA aqueous solution was prepared by stirring at 1,000 rpm using a homogenizer (Overhead (IKA)).

[0148] <Dispersed phase manufacturing>

[0149] 0.08 g of tirzepatide and 2 ml of dimethyl sulfoxide were weighed and added to an 8 mL vial, and stirred at 150 rpm to dissolve.

[0150] After the above solution was dissolved, 0.7 g of PLGA (inherent viscosity of 0.15 dL / g to 1.7 dL / g) and 2 ml of dichloromethane were added and stirred at 150 rpm to dissolve.

[0151] <Recovery of microspheres>

[0152] After the above process was completed, the dispersed phase was immediately taken with a syringe and placed in a 1 L reactor containing the continuous phase in advance, while stirring with a homogenizer for 7 seconds. The microspheres were then solidified for 24 hours. After solidification was complete, the microspheres were obtained by filtering through a 5 μm filter. The obtained microspheres were then freeze-dried in a freeze-dryer for more than 20 hours.

[0153]

[0154] Example 3: Preparation of tirzepatide microspheres

[0155] <Continuous phase manufacturing>

[0156] 1,000 mL of distilled water and 10 g of PVA were weighed and added to the reactor. A 1% (w / v) PVA aqueous solution was prepared by stirring at 1,000 rpm using a homogenizer (Overhead (IKA)).

[0157] <Dispersed phase manufacturing>

[0158] 0.175 g of tirzepatide and 2 ml of dimethyl sulfoxide were weighed and added to an 8 mL vial, and stirred at 150 rpm to dissolve.

[0159] After the above drug was dissolved, 0.7 g of PLGA (inherent viscosity of 0.15 dL / g to 1.7 dL / g) and 2 ml of dichloromethane were added and stirred at 150 rpm to dissolve.

[0160] <Recovery of microspheres>

[0161] After the above process was completed, the dispersed phase was immediately taken with a syringe and placed in a 1 L reactor containing the continuous phase in advance, while stirring with a homogenizer for 7 seconds. The microspheres were then solidified for 24 hours. After solidification was complete, the microspheres were obtained by filtering through a 5 μm filter. The obtained microspheres were then freeze-dried in a freeze-dryer for more than 20 hours.

[0162]

[0163] Example 4: Preparation of tirzepatide microspheres

[0164] <Continuous phase manufacturing>

[0165] 900 ml of distilled water was added to the reactor, and 4.5 g of PVA and 4.5 g of NaCl were weighed and added. A 0.5% (w / v) PVA aqueous solution was prepared by stirring at 1,000 rpm using a homogenizer (Overhead (IKA)).

[0166] <Preparation of Tirzepatide Solution>

[0167] 0.3 g of tirzepatide and 1.0 ml of distilled water were weighed and added to a 20 ml vial, and stirred at 150 rpm to dissolve.

[0168] <PLGA 용액의 제조>

[0169] 1.2 g of PLGA (inherent viscosity of 0.15 dL / g to 1.7 dL / g) was dissolved in 3 ml of dichloromethane and stirred at 300 rpm.

[0170] Emulsification

[0171] The PLGA solution prepared above was taken with a syringe and added to the tirzepatide solution, and then stirred at 20,000 rpm for 1 minute using a homogenizer (IKA).

[0172] <Recovery of microspheres>

[0173] After the above emulsification process was completed, the solution was immediately taken into a syringe and placed in a 1 L reactor containing the continuous phase in advance, while stirring using a homogenizer for 60 seconds. The microspheres were then solidified for 20 hours. After solidification was complete, the solution was filtered through a 5 μm filter to obtain microspheres (W / O / W type). The obtained microspheres were then freeze-dried in a freeze-dryer for more than 20 hours.

[0174]

[0175] Example 5: Preparation of tirzepatide microspheres

[0176] <Continuous phase manufacturing>

[0177] 900 ml of distilled water was added to the reactor, and 4.5 g of PVA and 4.5 g of NaCl were weighed and added. A 0.5% (w / v) PVA aqueous solution was prepared by stirring at 1,000 rpm using a homogenizer (Overhead (IKA)).

[0178] <Preparation of Tirzepatide Solution>

[0179] 0.386 g of tirzepatide and 1.5 ml of distilled water were weighed and added to a 20 ml vial, and stirred at 150 rpm to dissolve.

[0180] <PLGA 용액의 제조>

[0181] 0.9 g of PLGA (inherent viscosity of 0.15 dL / g to 1.7 dL / g) was dissolved in 3 ml of dichloromethane and stirred at 300 rpm.

[0182] Emulsification

[0183] The PLGA solution prepared above was taken with a syringe and added to the tirzepatide solution, and then stirred at 20,000 rpm for 1 minute using a homogenizer (IKA).

[0184] <Recovery of microspheres>

[0185] After the above emulsification process was completed, the solution was immediately taken into a syringe and placed in a 1 L reactor containing the continuous phase in advance, while stirring using a homogenizer for 60 seconds. The microspheres were then solidified for 20 hours. After solidification was complete, the solution was filtered through a 5 μm filter to obtain microspheres (W / O / W type). The obtained microspheres were then freeze-dried in a freeze-dryer for more than 20 hours.

[0186]

[0187] Example 6: Preparation of tirzepatide microspheres

[0188] <Continuous phase manufacturing>

[0189] 900 ml of distilled water was added to the reactor, and 4.5 g of PVA and 4.5 g of NaCl were weighed and added. A 0.5% (w / v) PVA aqueous solution was prepared by stirring at 1,000 rpm using a homogenizer (Overhead (IKA)).

[0190] <Preparation of Tirzepatide Solution>

[0191] 0.324 g of tirzepatide and 1 ml of distilled water were weighed and added to a 20 ml vial, and stirred at 150 rpm to dissolve.

[0192] <PLGA 용액의 제조>

[0193] 0.6 g of PLGA (inherent viscosity of 0.15 dL / g to 1.7 dL / g) was dissolved in 2 ml of dichloromethane and stirred at 300 rpm.

[0194] Emulsification

[0195] The PLGA solution prepared above was taken with a syringe and added to the tirzepatide solution, and then stirred at 20,000 rpm for 1 minute using a homogenizer (IKA).

[0196] <Recovery of microspheres>

[0197] After the above emulsification process was completed, the solution was immediately taken into a syringe and placed in a 1 L reactor containing the continuous phase in advance, while stirring using a homogenizer for 60 seconds. The microspheres were then solidified for 20 hours. After solidification was complete, the solution was filtered through a 5 μm filter to obtain microspheres (W / O / W type). The obtained microspheres were then freeze-dried in a freeze-dryer for more than 20 hours.

[0198]

[0199] Example 7: Preparation of tirzepatide microspheres

[0200] <Continuous phase manufacturing>

[0201] 900 ml of distilled water was added to the reactor, and 4.5 g of PVA and 4.5 g of NaCl were weighed and added. A 0.5% (w / v) PVA aqueous solution was prepared by stirring at 1,000 rpm using a homogenizer (Overhead (IKA)).

[0202] <Preparation of Tirzepatide Solution>

[0203] 0.269 g of tirzepatide and 1 ml of distilled water were weighed and added to a 20 ml vial, and stirred at 150 rpm to dissolve.

[0204] <PLGA 용액의 제조>

[0205] 0.5 g of PLGA (inherent viscosity of 0.15 dL / g to 1.7 dL / g) was dissolved in 2 ml of dichloromethane and stirred at 300 rpm.

[0206] Emulsification

[0207] The PLGA solution prepared above was taken with a syringe and added to the tirzepatide solution, and then stirred at 20,000 rpm for 1 minute using a homogenizer (IKA).

[0208] <Recovery of microspheres>

[0209] After the above emulsification process was completed, the solution was immediately taken into a syringe and placed in a 1 L reactor containing the continuous phase in advance, while stirring using a homogenizer for 60 seconds. The microspheres were then solidified for 20 hours. After solidification was complete, the solution was filtered through a 5 μm filter to obtain microspheres (W / O / W type). The obtained microspheres were then freeze-dried in a freeze-dryer for more than 20 hours.

[0210]

[0211] Example 8: Preparation of tirzepatide microspheres

[0212] <Continuous phase manufacturing>

[0213] 900 ml of distilled water was added to the reactor, and 4.5 g of PVA and 4.5 g of NaCl were weighed and added. A 0.5% (w / v) PVA aqueous solution was prepared by stirring at 1,000 rpm using a homogenizer (Overhead (IKA)).

[0214] <Preparation of Tirzepatide Solution>

[0215] 0.4 g of tirzepatide and 1 ml of distilled water were weighed and added to a 20 ml vial, and stirred at 150 rpm to dissolve.

[0216] <PLGA 용액의 제조>

[0217] 0.6 g of PLGA (inherent viscosity of 0.15 dL / g to 1.7 dL / g) was dissolved in 2 ml of dichloromethane and stirred at 300 rpm.

[0218] Emulsification

[0219] The PLGA solution prepared above was taken with a syringe and added to the tirzepatide solution, and then stirred at 20,000 rpm for 1 minute using a homogenizer (IKA).

[0220] <Recovery of microspheres>

[0221] After the above emulsification process was completed, the solution was immediately taken into a syringe and placed in a 1 L reactor containing the continuous phase in advance, while stirring using a homogenizer for 60 seconds. The microspheres were then solidified for 20 hours. After solidification was complete, the solution was filtered through a 5 μm filter to obtain microspheres (W / O / W type). The obtained microspheres were then freeze-dried in a freeze-dryer for more than 20 hours.

[0222]

[0223] Comparative Example 1: Preparation of Tirzepatide Microspheres

[0224] <Continuous phase manufacturing>

[0225] 900 ml of distilled water, 4.5 g of PVA (manufactured by Sigma), and 4.5 g of NaCl were weighed and added to the reactor. A 0.5% (w / v) PVA aqueous solution was prepared by stirring at 1,000 rpm using a homogenizer (Overhead (IKA)).

[0226] <Preparation of Tirzepatide Solution>

[0227] 0.24 g of tirzepatide and 2.4 ml of distilled water were weighed and added to a 20 ml vial, and stirred at 150 rpm to dissolve.

[0228] <PLGA 용액의 제조>

[0229] 4.8 g of PLGA (intrinsic viscosity of 0.10 dL / g to 0.31 dL / g) and PLGA (intrinsic viscosity of 0.32 dL / g to 0.74 dL / g) were dissolved in 12 ml of dichloromethane and stirred at 300 rpm.

[0230] Emulsification

[0231] The PLGA solution prepared above was taken with a syringe and added to the tirzepatide solution, and then stirred at 20,000 rpm for 1 minute using a homogenizer (IKA).

[0232] <Recovery of microspheres>

[0233] After the above emulsification process was completed, the solution was immediately taken into a syringe and placed in a 1 L reactor containing the continuous phase in advance, while stirring at 3,500 rpm using a homogenizer for 60 seconds. The microspheres were then solidified for 24 hours. After solidification was complete, the solution was filtered through a 5 μm filter to obtain microspheres (W / O / W type). The obtained microspheres were then freeze-dried in a freeze-dryer for more than 20 hours.

[0234]

[0235] Comparative Example 2: Preparation of tirzepatide microspheres

[0236] <Continuous phase manufacturing>

[0237] 900 ml of distilled water was added to the reactor, and 4.5 g of PVA and 4.5 g of NaCl were weighed and added. A 0.5% (w / v) PVA aqueous solution was prepared by stirring at 1,000 rpm using a homogenizer (Overhead (IKA)).

[0238] <Preparation of Tirzepatide Solution>

[0239] 0.323 g of tirzepatide and 1 ml of distilled water were weighed and added to a 20 ml vial, and stirred at 150 rpm to dissolve.

[0240] <PLGA 용액의 제조>

[0241] 0.6 g of PLGA (inherent viscosity 0.32 dL / g to 0.44 dL / g) was dissolved in 2 ml of dichloromethane and stirred at 300 rpm.

[0242] Emulsification

[0243] The PLGA solution prepared above was taken with a syringe and added to the tirzepatide solution, and then stirred at 20,000 rpm for 1 minute using a homogenizer (IKA).

[0244] <Recovery of microspheres>

[0245] After the above emulsification process was completed, the solution was immediately taken into a syringe and placed in a 1 L reactor containing the continuous phase in advance, while stirring using a homogenizer for 60 seconds. The microspheres were then solidified for 20 hours. After solidification was complete, the solution was filtered through a 5 μm filter to obtain microspheres (W / O / W type). The obtained microspheres were then freeze-dried in a freeze-dryer for more than 20 hours.

[0246]

[0247] Comparative Example 3: Preparation of tirzepatide microspheres

[0248] <Continuous phase manufacturing>

[0249] 900 ml of distilled water was added to the reactor, and 4.5 g of PVA and 4.5 g of NaCl were weighed and added. A 0.5% (w / v) PVA aqueous solution was prepared by stirring at 1,000 rpm using a homogenizer (Overhead (IKA)).

[0250] <Preparation of Tirzepatide Solution>

[0251] 0.41 g of tirzepatide and 1 ml of distilled water were weighed and added to a 20 ml vial, and stirred at 150 rpm to dissolve.

[0252] <PLGA 용액의 제조>

[0253] 0.6 g of PLGA (inherent viscosity 0.32 dL / g to 0.44 dL / g) was dissolved in 2 ml of dichloromethane and stirred at 300 rpm.

[0254] Emulsification

[0255] The PLGA solution prepared above was taken with a syringe and added to the tirzepatide solution, and then stirred at 20,000 rpm for 1 minute using a homogenizer (IKA).

[0256] <Recovery of microspheres>

[0257] After the above emulsification process was completed, the solution was immediately taken into a syringe and placed in a 1 L reactor containing the continuous phase in advance, while stirring using a homogenizer for 60 seconds. The microspheres were then solidified for 20 hours. After solidification was complete, the solution was filtered through a 5 μm filter to obtain microspheres (W / O / W type). The obtained microspheres were then freeze-dried in a freeze-dryer for more than 20 hours.

[0258]

[0259] Experimental Example 1: Confirmation of the loading rate of tirzepatide microspheres

[0260] The microspheres manufactured in Examples 1 to 8 and Comparative Example 1 were placed in a 20 ml volumetric flask and completely dissolved in acetonitrile containing 0.1% TFA (Trifluoroaceti Acid), then the solution was adjusted to the mark with distilled water containing 0.1% TFA (Trifluoroacetic Acid) and filtered through a 0.45 um syringe filter. This solution was detected using a UV detector using HPLC.

[0261] The results of the above experiment are shown in Table 1 below.

[0262] Theoretical loading rate (weight %) Actual loading rate (weight %) Example 1 109.35 Example 2 109.50 Example 3 2017.22 Example 4 2020.86 Example 5 3030.83 Example 6 3536.32 Example 7 3535.60 Example 8 4040.35 Comparative example 14.764.95 Comparative example 23535.34 Comparative example 34038.87

[0263] Experimental Example 2: Evaluation of in vitro release rate

[0264] The microspheres manufactured in Examples 1 to 8 were placed in a vial, and a pH 7.4 PBS solution was added. The vial was stirred at 100 rpm and maintained at 37°C. To measure the release amount over a certain period of time, the supernatant was taken and filtered through a 0.45 um RC filter to use as a test solution, and the new release solution was placed in a vial. The test solution was detected using an ultraviolet-visible spectrophotometer using HPLC.

[0265] The results of the above experiment are shown in Table 2.

[0266] Initial Excess Release (Wt%) 10th Day Release (Wt%) Example 1 2.3 3 4 9.55 Example 20.2 6 11.82 Example 3 12.8 1 3 3.21 Example 4 1.4 6 4 1.61 Example 5 1.4 7 4 7.62 Example 6 6.5 9 6.37 Example 7 11.7 8 7 9.14 Example 8 16.1 7 7 3.67 Comparative Example 25.0 0 8 7.06 Comparative Example 36.2 8 10 0.36

[0267] As confirmed in Table 2, the microspheres of Examples 1 to 8, in which tirzepatide is included in an amount of 9 wt% or more based on the total weight of the microspheres and the weight of the biocompatible polymer for tirzepatide is included in an amount of 91 wt% or less, exhibit an initial over-release of 20% or less within 24 hours, and long-term sustained release is possible. In addition, the microspheres of Comparative Examples 2 and 3, in which the biocompatible polymer is a copolymer of polylactide-co-glycolide (PLGA) having a molar ratio of lactide to glycolide of 50:45 to 55, exhibit a release rate of 85% or more on the 10th day, and long-term sustained release is difficult.

[0268] Therefore, it is preferable to use a copolymer of polylactide-co-glycolide (PLGA) having a molar ratio of lactide to glycolide of 50:45 to 55 as the biocompatible polymer.

[0269]

[0270] Experimental Example 3: In vivo pharmacokinetics test using beagles

[0271] After the above tirzepatide microparticle injection formulation (Example 5) was subcutaneously injected into a beagle, blood was collected at designated times, and the blood tirzepatide concentration was measured using LC-MS / MS.

[0272] The cumulative drug release rate of the above experimental results is shown in Figure 1.

[0273] As confirmed in Fig. 1, the microspheres of Example 5, in which tirzepatide is included in an amount of 9 wt% or more based on the total weight of the microspheres and the weight of the biocompatible polymer is included in an amount of 9 times or less based on the weight of the microspheres, have no initial excessive release and have excellent sustained-release capability for a long period of time.

Claims

1. Microspheres comprising tirzepatide or a pharmaceutically acceptable salt thereof and a biocompatible polymer, The above tirzepatide or a pharmaceutically acceptable salt thereof is contained in an amount of 9 wt% or more based on the total weight of the microparticles, The biocompatible polymer is a microsphere having an intrinsic viscosity of 0.15 dL / g to 1.7 dL / g and a molar ratio of lactide to glycolide of 50:45 to 55.

2. In paragraph 1, Microspheres characterized in that the biocompatible polymer is contained in an amount of 91% or less by weight based on the total weight of the microspheres.

3. In paragraph 1, The above microspheres are microspheres characterized in that the release of tirzepatide or a pharmaceutically acceptable salt thereof continues for 20 days or more.

4. In paragraph 3, Microspheres characterized in that the tirzepatide or a pharmaceutically acceptable salt thereof contained in the above microspheres has an initial burst of 30% or less.

5. In paragraph 1, The above microspheres are characterized by being of the O / W (oil-in-water) type or the W1 / O / W2 (water-in-oil-in-water) type. 6.(a) A step of preparing a dispersion phase by dispersing tirzepatide or a pharmaceutically acceptable salt thereof and a biocompatible polymer in one or more solvents; (b) a step of adding the manufactured dispersion phase to a continuous phase and stirring to form microspheres; and (c) A method for producing microparticles, comprising the step of removing the solvent.

7. In paragraph 6, A method for producing microspheres, characterized in that the weight ratio of the biocompatible polymer to tirzepatide or a pharmaceutically acceptable salt thereof in the step (a) is 9 times or less.

8. In paragraph 6, A method for producing microspheres, characterized in that the biocompatible polymer in the above step (a) has an intrinsic viscosity of 0.15 dL / g to 1.7 dL / g.

9. In paragraph 6, A method for producing microspheres, characterized in that the biocompatible polymer is polylactide-co-glycolide (PLGA) having an intrinsic viscosity of 0.15 dL / g to 1.7 dL / g and at least one selected from copolymers having a molar ratio of lactide to glycolide of 50:45 to 55. 10.(1) A step of preparing an inner phase (W1) by dissolving or dispersing tirzepatide or a pharmaceutically acceptable salt thereof in a solvent; (2) A step of preparing an oil phase (O) by dissolving a biocompatible polymer in one or more solvents; (3) A step of dispersing an internal phase (W1) in the oil phase (O) to prepare a water-in-oil (W1 / O) type emulsion; (4) A step of forming microspheres by dispersing the water-in-oil (W1 / O) type emulsion into an external continuous phase (W2) to produce a water-in-oil (W1 / O / W2) type emulsion; and (5) A method for producing microparticles, comprising a step of removing the solvent.

11. In paragraph 10, A method for producing microspheres, characterized in that the weight ratio of the biocompatible polymer to tirzepatide or a pharmaceutically acceptable salt thereof in the above step (3) is 9 times or less.

12. A pharmaceutical composition for the prevention or treatment of diabetes, obesity, hypertension, hyperlipidemia, non-alcoholic steatohepatitis, metabolic steatohepatitis, cardiovascular disease, or degenerative neurological disease, comprising the microparticles of paragraph 1 and a pharmaceutically acceptable carrier.

13. In paragraph 12, A pharmaceutical composition characterized in that the above pharmaceutical composition is for subcutaneous or intramuscular injection.

Citation Information

Patent Citations

  • Method for producing microspheres loaded with drugs and microspheres loaded with drugs produced thereby

    KR100918092B1

  • The method of separating and purifying cellular components using non-covalent bond between a cucurbituril derivative and a guest compound and an apparatus using the same

    KR1020090109809A

  • Method of automatically doffing the full bobbin packages from, and donning the empty bobbin tubes onto, the spindles of a preparatory spinning machine

    US4389840A

  • Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents

    US4530840A

  • Sustained release microcapsule for water soluble drug

    US5271945A